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Serum interferon (IFN)-α concentrations are elevated in 
patients with systemic lupus erythematosus (SLE) [1] and 
contribute to the break of peripheral tolerance by 
sustaining the diﬀ  erentiation of myeloid dendritic cells 
[2]. IFN-α actually increases the diﬀ  erentiation of mono-
cytes into dendritic cells that present antigens from dying 
cells to CD4+ lymphocytes, resulting in their proliferation. 
Th   e involvement of IFN-α in SLE development is further 
supported by the IFN-inducible gene expression signa-
ture that characterizes a clinical subset of patients with 
SLE and more severe disease (for example, damage of the 
kidneys or the central nervous system) [3]. Plasmacytoid 
dendritic cells (PDCs) have been suggested to be the 
main cells producing IFN-α [4], and an inducer of IFN-α 
has been identiﬁ  ed in the circulation of patients with SLE 
[5]. Currently, PDCs activated by DNA- and RNA-
contain  ing immune complexes are believed to be the 
main source of IFN-α in SLE upon triggering of Toll-like 
receptor (TLR) 9 and TLR7, respectively, in cooperation 
with CD32 [6-8]. Nevertheless, PDC deple  tion experi-
ments suggest that other cell types produce IFN-α in SLE 
[2] and type I IFN production occurs independently of 
Fcγ receptors in a lupus mouse model [9], indicating that 
uptake of immune complexes is not required. In a 
diﬀ  erent lupus mouse model, the double-stranded RNA 
analog poly I:C was shown to induce IFN-α production in 
spleen monocytes [10], conﬁ  rming that – depending on 
the stimulus – cells other than PDCs may produce IFN-α 
independently of the presence of immune complexes.
Interestingly, Fairhurst and colleagues [11] recently 
showed that type I IFNs are produced by resident renal 
cells, suggesting that locally produced IFN-α may pro-
mote glomerulonephritis development. Moreover, this 
mecha  nism seems to involve the recruitment of neutro-
phils (polymorphonuclear leukocytes, or PMNs). In agree-
ment with those results, granulocytes are activated in 
active SLE as suggested by the overexpression of granulo-
poiesis-related genes, known as the granulo  poiesis 
signature [12]. Th  is microarray analysis per  formed on 
blood cells suggests that granulocytes are involved in SLE 
pathogenesis. Moreover, PMNs are about 200 times more 
abundant than PDCs in the blood and are the ﬁ  rst cells 
recruited at sites of inﬂ  ammation. PMNs play a central 
role in host defense and, once activated, produce 
proinﬂ  ammatory cytokines and reactive species. How  ever, 
upon inappropriate activation, PMN-derived products 
may induce tissue damage. PMNs express TLRs 1 to 10 
(except TLR3) and link innate and adaptive immunity by 
inﬂ   uencing, for example, dendritic cells. Importantly, 
PMNs are capable of producing IFN-α in response to 
some stimuli [13]. Normal and lupus PMNs, however, 
were not compared and only granulo  cyte colony-stimu-
lat  ing factor (G-CSF), in contrast to lipopolysaccharide 
(LPS) or N-formyl-methionine-leucine-phenylalanine 
(fMLP), was shown to induce IFN-α mRNA transcripts. 
A recent study conﬁ  rmed the latter observation by using 
PMNs isolated from patients with SLE and described the 
induction of type I IFN upon activation with G-CSF, 
phorbol 12-myristate 13-acetate (PMA), or transfected 
poly I:C, although the natural lupus stimulus and the 
mechanism involved were not identiﬁ   ed [14]. Th  e 
Abstract
Interferon-α plays a crucial role in the pathogenesis 
of systemic lupus erythematosus. Nevertheless, the 
diff  erent human cell types producing this cytokine as 
well as the stimuli inducing its production have not 
been completely characterized. So far, a subpopulation 
of dendritic cells activated by immune complexes has 
been identifi  ed as major producers of interferon-α in 
patients with lupus. However, those cells represent 
a minor population and some studies have reported 
the secretion of interferon-α by other cells. On the 
other hand, more than 50% of blood leukocytes 
are neutrophils and their functions are still not fully 
understood. Recent data suggest that neutrophils, 
though usually not considered interferon-α-producing 
cells, may represent an unexpected source of this 
cytokine in response to some lupus stimuli.
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PMNs secreting increased levels of several cytokines, 
such as tumor necrosis factor (TNF) and IFN-γ (upon 
activa  tion), and may induce vascular damage. Th  ose  cells 
are low-density PMNs and represent an abnormal subset 
of neutrophils present in peripheral blood mononuclear 
cell (PBMC) preparations from patients with lupus. Low-
density PMNs present features of both immature and 
activated PMNs and have a decreased phagocytic poten-
tial, but it is still unknown whether they represent a 
distinct cell population. It should be noted that another 
study has shown that human PMNs isolated from healthy 
donors also produce IFN-β mRNA upon stimulation with 
transfected poly I:C [15], although IFN-α/β secretion was 
not detected. Likewise, mouse PMNs infected with 
encephalomyocarditis virus express IFN-β mRNA, a 
mechanism partially dependent on the cytoplasmic RNA 
helicase MDA5. In regard to IFN-α, we could show that 
PMNs activated by chromatin, a major autoantigen in 
SLE, produced IFN-α in an immune complex-indepen-
dent manner whereas non-stimulated PMNs did not 
(Dennis Lindau and colleagues, University of Paris 13, 
France, manuscript submitted). Mono-nucleosomes were 
particularly eﬃ     cient in inducing PMN activation. In 
contrast to the ﬁ  ndings of Denny and colleagues  [14], 
IFN-α production was detected in steady-state PMNs 
and with PMNs isolated from both patients with SLE and 
healthy donors, suggesting that a key event is the 
presence of increased concentrations of circulating 
nucleo  somes, a situation especially common in vivo in 
patients with SLE. Together with our previous results 
showing that free chromatin stimulates PMNs [16] 
independently of TLR9 [17], leading to interleukin (IL)-8, 
IL-6, and TNF secretion, CD11b upregulation, and 
increased phagocytic activity, all of those studies reveal 
an unsuspected role for PMNs in SLE pathogenesis. 
Nevertheless, further studies will be needed to identify 
the pathway elicited. A cellular cross-talk might be 
required to eﬃ   ciently trigger IFN-α secretion by PMNs. 
Owing to their proinﬂ  ammatory activity [18,19], platelets 
might be involved. Indeed, platelets activated by immune 
complexes were recently shown to potentiate IFN-α 
secretion by PDCs in SLE through a CD154-CD40 
interaction [20]. Depending on the stimulus, activated 
PMNs may secrete IFN-α early during the lupus disease, 
before immune complexes are produced, bypassing the 
classical mechanism requiring the induction of 
autoantibodies and the formation of immune complexes 
activating PDCs. Th  us, two complementary pathways 
might be involved in IFN-α induction in SLE.
Conclusions
Because IFN-α secretion is a key pathogenic event in 
SLE, the characterization of the cellular sources and the 
lupus stimuli represents a crucial step for the develop-
ment of new therapeutic strategies aiming at controlling 
IFN-α secretion, especially at an early stage of the disease. 
Because they are abundant and recruited in inﬂ  amed 
tissues, activated PMNs may represent a new therapeutic 
target. Finally, future studies will be necessary to 
determine whether neutrophil extracellular traps (NETs) 
are involved in the induction of IFN-α production by 
PMNs and reciprocally whether circulating chromatin 
triggers the formation of NETs. Indeed, NETs are struc-
tures formed by activated PMNs and contain chromatin 
[21]. Because they form ﬁ  bers that bind and kill bacteria, 
NETs represent a type of innate response. In particular, 
mature SLE PMNs have been shown very recently to 
release immunogenic NETs upon exposure to auto  anti-
bodies, leading to an activation-induced cell death named 
NETosis, and those lupus NETs trigger the production of 
IFN-α by PDCs in a TLR9-dependent manner [22,23]. 
Interestingly, this mechanism occurs in IFN-α-primed 
PMNs, implying that IFN-α had already been induced. 
Collectively, the data suggest that PMN-derived or PMN-
induced IFN-α or both might have been underestimated.
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